Results 161 to 170 of about 140,144 (311)

Current role of colony stimulating factors in the management of neutropenia

open access: yes, 2017
Colony stimulating factors are naturally occurring proteins that promote the growth. Synthesized versions exist that bind the same receptors, often acting in the same ways as their organic counterparts.
Al-kharouf, Issa
core  

A new perspective on cancer treatment: the interaction and application prospect between ICIs and radiotherapy

open access: yesPrecision Radiation Oncology, EarlyView.
The combination of immune checkpoint inhibitors (ICIs) and radiotherapy synergistically enhances efficacy through an “antigen release‐immune activation” closed‐loop mechanism, significantly improving outcomes in solid tumors (e.g., lung cancer, melanoma).
Guiling Song   +5 more
wiley   +1 more source

Advances in mucosal injury mechanisms in radiation‐induced esophagitis associated with thoracic radiotherapy

open access: yesPrecision Radiation Oncology, EarlyView.
There is no specific therapeutic drug regimen for radiation esophagitis. In previous studies, radiation esophagitis was considered a self‐limiting disease; however, current clinical approaches are limited to symptomatic treatment, which yields unsatisfactory therapeutic outcomes.
Hao Zhang   +7 more
wiley   +1 more source

Non‐Cancer Causes of Death in Patients With Metastatic Hormone‐Sensitive Prostate Cancer: A Real‐World Analysis

open access: yesThe Prostate, EarlyView.
ABSTRACT Background As overall survival improves in metastatic hormone‐sensitive prostate cancer (mHSPC), non‐cancer causes of death are increasingly relevant. Methods We conducted a real‐world multicenter study of patients diagnosed with mHSPC treated with ADT alone or in combination. Causes of death before progression to castration‐resistant prostate
Marta Garcia de Herreros   +15 more
wiley   +1 more source

Exposure-safety analyses of talazoparib in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in the TALAPRO-2 trial. [PDF]

open access: yesJ Pharmacokinet Pharmacodyn
Wang Y   +9 more
europepmc   +1 more source

Semi‐mechanistic population PK/PD model to aid clinical understanding of myelodysplastic syndromes following treatment with Venetoclax and Azacitidine

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 448-459, March 2025.
Abstract Myelodysplastic syndromes (MDS) represent a group of bone marrow disorders involving cytopenias, hypercellular bone marrow, and dysplastic hematopoietic progenitors. MDS remains a challenge to treat due to the complex interplay between disease‐induced and treatment‐related cytopenias.
Neha Thakre   +5 more
wiley   +1 more source

Mesenchymal stromal cell therapy for rheumatoid arthritis: Long‐term efficacy, safety, and mechanistic insights

open access: yesRheumatology &Autoimmunity, EarlyView.
Graphical abstract summarizing the multifactorial pathogenesis of rheumatoid arthritis (RA) and the therapeutic potential of mesenchymal stromal cell (MSC) therapy. MSCs provide promising benefits through their immunomodulatory properties, low immunogenicity, ability to promote tissue repair, and multi‐lineage differentiation, presenting a potential ...
Yingjia Chen   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy